Fluoresentric Names Lynda A. Merrill CEO

PARK CITY, Utah--(BUSINESS WIRE)--Fluoresentric, Inc. announced effective July 28, 2016, Lynda A. Merrill has assumed the position of CEO previously held by William C. Olson. Ms. Merrill has extensive leadership experience in the diagnostics industry, including senior management positions at QIAGEN, Boehringer Mannheim, Gen-Probe and Immunodiagnostic Systems. She is currently a board member of Fluoresentric subsidiary XCR Diagnostics, a position she will continue to hold as CEO of Fluoresentric.

“I believe the XCR technology has the potential to be transformative and I look forward to working with Brian and the teams at Fluoresentric.”

“Lynda has an exceptional track record of success in our industry and we are excited that she has taken on the role of CEO,” stated Brian Caplin, PhD, Founder of Fluoresentric. “She has the experience we need to take Fluoresentric to the next level.”

Ms. Merrill has almost 30 years’ experience in the diagnostics industry, including 10 years at Gen-Probe during its strongest period of growth. She was a member of the executive team, holding a number of roles, including Vice President Industrial Relationships and Vice President of World Wide Marketing and Sales. She was also a member of the team that took Gen-Probe public in 2002. After Gen-Probe, Ms. Merrill was Vice-President Molecular Diagnostics Sales, EMEAA, for QIAGEN and Global Head of Sales and Marketing for IDS. She also has extensive international experience, having lived in Europe for eight years and has traveled extensively throughout Europe, Asia and the Middle East.

“I am excited to take the position of CEO of Fluoresentric,” said Ms. Merrill, “I believe the XCR technology has the potential to be transformative and I look forward to working with Brian and the teams at Fluoresentric.”

About Fluoresentric, Inc.

Fluoresentric, Inc., an Intellectual Property company, is positioned to monetize its XCR technology portfolio globally. With strong intellectual property initially in molecular amplification, the Company has expanded its intellectual property collection into instrumentation, sample prep and other application chemistries. Fluoresentric’s vision is to apply the Company’s intellectual property to an extensive set of commercial opportunities, resulting in better and faster results processing for healthcare and other industries worldwide.